To understand JMML development within the stem cell compartment and to identify new therapeutic targets, we have characterized the histone modifications and chromatin accessibility in the CD34+ compartment of five PTPN11-mutated JMML spleen-derived HSPCs. This evidence concerns the gene PTPN11 and juvenile myelomonocytic leukemia.